Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw its stock touch a 52-week low of $518.68 as the biotech firm contends with heightened market volatility and shifting investor sentiment. The stock ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron (REGN) stock price corrected sharply in recent months. ... in which I argued, based on technical analysis, market sentiment analysis, and catalysts, ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet ...

Over the past five years, Regeneron Pharmaceuticals' total shareholder return reached 46.55%, showcasing its resilience amidst a challenging market. This period witnessed several pivotal developments.

Data & APIs. Events. Premarket ...

A few months back in December 2020, we discussed why Regeneron stock looks undervalued. The stock since then has had a volatile ride with gains of 7% between early December 2020 and late January ...

Regeneron Pharmaceuticals’ Debt total was $2.7 Billion at the conclusion of the most recent quarter, while its market capitalization is $52 Billion (as of 5/30/2025).

Dupixent sales were $3.7 billion in the quarter, up 15% year over year, and Regeneron’s collaboration revenue from Sanofi was 1.2 billion, or a 22% year-on-year increase.

Regeneron Pharmaceuticals has delivered market-beating results for shareholders over the prior 10 years. With competition heating up, however, the biotech may be entering a period of slowing growth.